Circadian Technologies Limited (ASX: CIR) is an Australian biotechnology company developing innovative, biologics-based therapies for the treatment of cancer and other serious human illnesses.
Circadian owns an extensive portfolio of products and intellectual property related to Vascular Endothelial Growth Factors (VEGFs), a class of proteins that play a critical role in regulating tumour blood supply. These programs are conducted through Vegenics Ltd, a wholly-owned subsidiary of Circadian.
Latest Media Releases
Circadian Technologies (ASX:CIR; OTCQX:CKDXY) announced today that a commissioned reports by a leading healthcare analyst, Edison Investment Research based in London, was published last night and is a…
8 years ago
19 Dec 2011 – Circadian Technologies Limited (ASX:CIR), CEO and managing director, Robert Klupacs, talks about applications for its VGX-100 therapy in the treatment of a range of s…
9 years ago
14 Feb 2011 – Circadian Technologies Limited (ASX:CIR), CEO, Robert Klupacs, explains what the deal means, reports on its successful patent extensions and progress with its diagnos…
9 years ago
05 Oct 2010 – Circadian Technologies Limited (ASX:CIR), CEO, Robert Klupacs, introduces the company, its biologics-based therapies for cancer, product pipeline and commercial partn…